Inovio Pharmaceuticals’ VGX-3100 therapeutic synthetic cancer vaccine has demonstrated that a DNA-based therapeutic vaccine can produce immune responses to kill target cells.

The clinical results indicate that its VGX-3100 therapeutic synthetic vaccine is capable of driving immune responses to antigens from high-risk types of human papilloma virus (HPV) infection and immune responses displayed a killing effect on cells changed by HPV into precancerous dysplasias.

Inovio president and CEO Dr. Joseph Kim said that the results indicate that a DNA-based immune therapy can generate potent and durable T-cell responses in people.

"Our ongoing phase II efficacy trial is designed to show that the immune responses seen in this study, in particular the generation of killer T-cell responses, may reverse cervical disease caused by chronic HPV infection," Dr. Kim added.

"The type of T-cell killing activity seen in this new data provides a growing foundation for efficacy trials focused on the treatment of HPV-associated cancers including cervical, head and neck, and anogenital cancers."

According to the phase I trial study data, 100% of patients (18 of 18) demonstrated antigen-specific antibody responses to Inovio’s vaccine, while 78% showed T-cell responses in the validated ELISpot assay.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

T-cell immunity tests measured the ability of CD8+ T-cells from vaccinated patients to kill cells displaying HPV antigens on their surface, 91% of patients who developed T-cell responses showed the presence of CD8+ T-cells capable of this type of killing activity.

A current phase II trial is assessing the ability of its DNA-based VGX-3100 to treat cervical dysplasias caused by HPV infection.